Keith Meister – Chairman

SIGNIFICANT EXPERIENCE AS OWNER/OPERATOR AND PUBLIC COMPANY BOARD MEMBER

Founder and CIO of Corvex Management, which manages $2.5bn, targeting high quality businesses that can benefit from constructive shareholder engagement, while generating a 20% annual return for shareholders. Served as director of 15 public companies and helped structure and execute over $80bn in transactions. Previously Vice Chairman and CEO of Icahn Enterprises. During Keith’s tenure assets grew from $1.5 billion to $18 billion while generating substantial shareholder returns. Served as director of 15 public company boards. History of creating shareholder value through improved corporate governance, capital allocation and operations.

Tara Comonte – Board Member

Tara Comonte has been CEO of TMRW Life Sciences, Inc., the creator of the world’s first and only robotic and SaaS platform for automated cell management platform in the fast-growing in vitro fertilization (IVF) sector, since May 2021. Tara was a founding member of TMRW’s Board of Directors in 2018 and is a passionate advocate for driving innovation and accelerated use of technology to benefit women’s health and the broader fertility sector. TMRW’s platform is being implemented across leading IVF clinics in the US in 2021 and will expand commercial operations to the UK and Europe in 2022. Previously President and CFO at Shake Shack (NYSE: SHAK), the high growth, global, publicly traded restaurant chain, Tara was instrumental in the company’s accelerated implementation of people- and customer-first digital and technology solutions, resulting in significant value creation, and oversaw a host of additional enterprise-wide technology initiatives. Prior to Shake Shack, Tara held C-level positions at large public and private equity owned media companies, including Getty Images and McCann Worldgroup, part of Fortune 500 public company Interpublic Group (NYSE: IPG). Tara received a B.A. in Accounting and Finance from Heriot-Watt University.

Michael Egholm, Ph.D. – Board Member

Michael Egholm, Ph.D., was the Chief Technology Officer of Danaher Life Sciences and created and led Danaher’s corporate venture fund from 2017 until September 2021. Previously, he was the President of Biopharmaceuticals at Pall Corporation since 2014, and joined Pall as its Chief Technology Officer in 2010. Dr. Egholm has over 25 years of proven leadership in developing and commercializing innovative technologies and previously served as Chief Technology Officer at 454 Life Sciences Corporation, the first company to successfully commercialize Next Gen Sequencing (NGS). Prior to joining 454, Dr. Egholm held senior R&D positions with Molecular Staging and Applied Biosystems. Furthermore, Dr. Egholm is an elected member of the Royal Danish Academy of Sciences and Letters, a named inventor on numerous patents, and co-author of many high profile papers. Michael currently serves as a director of Isoplexis and Abbratech. Michael earned his Ph.D. In chemistry from University of Copenhagen.

Demetrios Kouzoukas – Board Member

Mr. Kouzoukas is a member of the Board of Directors for Clover Health. From 2017-2021, he was the Chief Executive of the Medicare program at the Centers for Medicare & Medicaid Service, where he worked with providers, insurers, and manufacturers to ensure equitable access to health care. As manager of the largest healthcare payor in the U.S., he delivered lower payment error rates year over year, brought about reductions in Medicare Advantage premiums, and rewired policies and operations in response to the COVID pandemic. From 2003-2009, he played a leading role in the Department’s broad portfolio of agencies and activities, from the FDA to the Office for Civil Rights, while serving first as Deputy General Counsel and then Associate Deputy Secretary at HHS. He was appointed to the Administrative Conference of the U.S. to represent the public as an expert in public administration and health benefits. Mr. Kouzoukas received a B.A. in Political Science/Public Policy from The George Washington University, and a J.D. from the University of Illinois College of Law.